Patents Examined by Karl J. Puttlitz
  • Patent number: 11951109
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: April 9, 2024
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
  • Patent number: 11951175
    Abstract: The present invention is based on the surprising finding that the linker employed in a bioconjugate, such as an anti-body-drug conjugate, is not therapeutically inert but has an effect on the therapeutic index of the bioconjugate. The present invention thus concerns a method for increasing the therapeutic index of a bioconjugate and the bioconjugates for use in treatment, in particular cancer. The bioconjugates according to the invention have a sulfamide linker comprising a group according to formula (1).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: April 9, 2024
    Assignee: Synaffix B.V.
    Inventors: Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Petrus Josephus Jacobus Maria Van De Sande, Remon Van Geel, Floris Louis Van Delft, Sander Sebastiaan Van Berkel
  • Patent number: 11939241
    Abstract: The present invention relates generally to stable percarboxylic acid compositions comprising, inter alia, at least two stabilizing agents, and various uses for water treatments, including water treatments in connection with oil- and gas-field operations. The present invention also relates to slick water compositions and gel based compositions that comprise stable percarboxylic acid compositions and the use thereof in oil- and gas-field operations.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 26, 2024
    Assignee: ECOLAB USA INC.
    Inventors: Junzhong Li, David McSherry, Allison Brewster, Richard Staub, Renato De Paula, John Wilhelm Bolduc, Robert J. Ryther, Victor V. Keasler
  • Patent number: 11938177
    Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: March 26, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Robert Seder, Geoffrey Lynn
  • Patent number: 11938124
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: March 26, 2024
    Assignee: PMV Pharmaceuticals, Inc.
    Inventors: Arnold Levine, Melissa Dumble
  • Patent number: 11931420
    Abstract: The present disclosure relates to methods of using antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs in combination with a gamma secretase inhibitor (GSI), such as in therapeutic methods. Also provided are pharmaceutical compositions and kits comprising the antibody conjugates and GSI.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 19, 2024
    Assignee: CELGENE CORPORATION
    Inventor: Kaida Wu
  • Patent number: 11931422
    Abstract: Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 19, 2024
    Assignee: HELIX BIOPHARMA CORPORATION
    Inventors: Heman Chao, Wah Yau Wong, Baomin Tian, Kimberly Jayne Gaspar, Praveen Kumar
  • Patent number: 11932601
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo
  • Patent number: 11925691
    Abstract: One aspect of the present invention provides a compound in which a functional group capable of binding to a globulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidic polymer and a functional group capable of a click reaction is introduced at the other end; a polypeptide conjugate in which a physiologically active polypeptide binds to one end of the compound; a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region bind to both ends thereof by using the compound as a linker; and methods for preparing the same compound, polypeptide conjugate, and physiologically active polypeptide conjugate.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: March 12, 2024
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Su Yeon Park, Dae Jin Kim, Sung Youb Jung, Yong Gyu Jung, Hyun Sik Yun
  • Patent number: 11911435
    Abstract: A conjugate and preparation method therefor, comprising a medication composition comprising the conjugate and a use of the medication composition in preparing medications for the treatment or prevention of diseases.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: February 27, 2024
    Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
    Inventors: Gang Qin, Jinduo Yuan, Lu Jiang, Chubing Tan, Lili Shi, Cao Lv, Leilei Chen
  • Patent number: 11911434
    Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: February 27, 2024
    Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
    Inventors: Gang Qin, Jinduo Yuan, Lu Jiang, Chubing Tan, Lili Shi, Cao Lv, Leilei Chen
  • Patent number: 11911359
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: February 27, 2024
    Assignee: PDS Biotechnology Corporation
    Inventors: Weihsu Chen, Weili Yan, Kenya Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Patent number: 11906527
    Abstract: The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: February 20, 2024
    Assignee: AMBERGEN, INC.
    Inventors: Mark J. Lim, Gargey Yagnik, Kenneth J. Rothschild
  • Patent number: 11903925
    Abstract: Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 20, 2024
    Assignee: RepoCeuticals A/S
    Inventor: Lars Otto Uttenthal
  • Patent number: 11903948
    Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: February 20, 2024
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Zhenwei Miao, Jing Wang, Gang Chen, Yan Qing, Tong Zhu, Liang Xiao, Hong Zhang, Qiuyan Yang, Dylan Dalun Deng, Liping Liu, Hong Zeng, Li Yin, Qifeng Shi, Hongmei Song, Xi Zhao, Lichun Wang, Jingyi Wang
  • Patent number: 11897952
    Abstract: Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 13, 2024
    Inventors: John Williams, Krzysztof P. Bzymek, David Horne, Jun Xie
  • Patent number: 11884730
    Abstract: A method of sensitizing cancer to immunotherapy in a subject in need thereof includes administering to the subject a therapeutically effective amount of a CdK5 inhibitor to suppress immune checkpoint PD-L1.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: January 30, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Agne Petrosiute
  • Patent number: 11879010
    Abstract: This invention relates to methods and compositions comprising antibodies or fragments thereof comprising a targeting ligand and engineered cytotoxic cells comprising a targeting agent specific for the targeting ligand, for use in inducing cytotoxicity in a cancer cell, in delivering a cytotoxic cell to a cancer cell in a subject, and in treating cancer.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: January 23, 2024
    Assignee: The Charlotte Mecklenburg Hospital Authority
    Inventor: Steven Park
  • Patent number: 11877988
    Abstract: This disclosure provides multifunctional conjugate molecules comprising a target binding component covalently linked to one or more cannabinoids and/or one or more cannabinoid conjugate components. In some embodiments, the target binding component also is covalently linked to one or more active agent components. The disclosed conjugate molecules are designed to deliver therapeutic benefits of each component of the conjugate molecules and can be used to treat cancer and other disorders.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: January 23, 2024
    Assignee: Diverse Biotech, Inc.
    Inventors: Paul Hershberger, Philip Arlen
  • Patent number: 11850262
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 26, 2023
    Assignees: Purdue Research Foundation, Endocyte, Inc.
    Inventors: Philip Stewart Low, Haiyan Chu, Yong Gu Lee, Yingjuan J. Lu, Christopher Paul Leamon, Leroy W. Wheeler, II